Literature DB >> 8686502

Intermittent treatment with human parathyroid hormone (hPTH[1-34]) increased trabecular bone volume but not connectivity in osteopenic rats.

N E Lane1, J M Thompson, G J Strewler, J H Kinney.   

Abstract

Previous studies have determined that intermittent parathyroid hormone (PTH) therapy increases bone mass and improves biomechanical strength in osteopenic animal models. The purpose of this investigation was to determine if intermittent human parathyroid hormone (hPTH[1-34]) therapy increased trabecular bone volume and connectivity in a rat model of established osteopenia using three-dimensional (3D) ex vivo in situ morphometry by X-ray tomographic methods (XTM). Six-month-old retired Sprague-Dawley breeder rats were used. Thirty animals were ovariectomized (OVX) and six were Sham operated. On day 56, post-OVX, a prePTH-treatment OVX groups was sacrificed. The remaining OVX animals were randomized into four groups of six animals each, given injections 5 out of every 7 days for 28 days of either vehicle or hPTH(1-34) at 4, 40, or 400 microg/kg of body weight (BW)/day and were sacrificed on day 84 post-OVX. At sacrifice, the left proximal tibias were harvested for XTM scans. hPTH(1-34) at medium and high doses significantly increased trabecular bone volume and trabecular thickness compared with ovariectomized animals treated with vehicle (p<0.05). The trabecular bone volume was equal to or greater than the Sham-operated animals in both hPTH(1-34) 40 and 400 microg/kg of BW treatment groups. Trabecular bone connectivity decreased by nearly 50% compared to the S ham-operated group at day 84 post-OVX and did not increase with any of the hPTH(1-34) treatments. Intermittent hPTH(1-34) treatment is osteopenic OVX rats increased trabecular bone volume to control levels or higher by thickening existing trabeculae. Human PTH(1-34) did not re-establish connectivity when therapy was started after 50% of the trabecular connectivity was lost. We hypothesize that to re-establish trabecular connectivity, a therapeutic intervention would have to be given before a significant distance between trabeculae has developed. Further studies will need to be done to refute or confirm our hypothesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8686502     DOI: 10.1002/jbmr.5650101007

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  17 in total

Review 1.  Mechanisms of bone loss and gain in untreated and treated osteoporosis.

Authors:  Juliet Compston
Journal:  Endocrine       Date:  2002-02       Impact factor: 3.633

Review 2.  Current technologies in the evaluation of bone architecture.

Authors:  Sharmila Majumdar
Journal:  Curr Osteoporos Rep       Date:  2003-12       Impact factor: 5.096

Review 3.  Current diagnostic techniques in the evaluation of bone architecture.

Authors:  Thomas M Link; Sharmila Majumdar
Journal:  Curr Osteoporos Rep       Date:  2004-06       Impact factor: 5.096

4.  Bone microarchitecture in males with corticosteroid-induced osteoporosis.

Authors:  D Chappard; N Josselin; C Rougé-Maillart; E Legrand; M F Baslé; M Audran
Journal:  Osteoporos Int       Date:  2006-11-22       Impact factor: 4.507

Review 5.  Parathyroid hormone in the treatment of involutional osteoporosis: back to the future.

Authors:  J Y Reginster; A N Taquet; G Fraikin; C Gosset; B Zegels
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

6.  Basic fibroblast growth factor improves trabecular bone connectivity and bone strength in the lumbar vertebral body of osteopenic rats.

Authors:  Wei Yao; Tamer Hadi; Yebin Jiang; Jeff Lotz; Thomas J Wronski; Nancy E Lane
Journal:  Osteoporos Int       Date:  2005-08-05       Impact factor: 4.507

7.  Positive skeletal effects of cladrin, a naturally occurring dimethoxydaidzein, in osteopenic rats that were maintained after treatment discontinuation.

Authors:  K Khan; K Sharan; G Swarnkar; B Chakravarti; M Mittal; T K Barbhuyan; S P China; M P Khan; G K Nagar; D Yadav; P Dixit; R Maurya; N Chattopadhyay
Journal:  Osteoporos Int       Date:  2012-08-30       Impact factor: 4.507

8.  Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial.

Authors:  N E Lane; S Sanchez; G W Modin; H K Genant; E Pierini; C D Arnaud
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

9.  Endogenous FGF-2 is critically important in PTH anabolic effects on bone.

Authors:  Maria Giovanna Sabbieti; Dimitrios Agas; Liping Xiao; Luigi Marchetti; J Douglas Coffin; Thomas Doetschman; Marja M Hurley
Journal:  J Cell Physiol       Date:  2009-04       Impact factor: 6.384

10.  Basic fibroblast growth factor forms new trabeculae that physically connect with pre-existing trabeculae, and this new bone is maintained with an anti-resorptive agent and enhanced with an anabolic agent in an osteopenic rat model.

Authors:  N E Lane; J Kumer; W Yao; T Breunig; T Wronski; G Modin; J H Kinney
Journal:  Osteoporos Int       Date:  2003-05-24       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.